26 aug 25   ekf diagnostics hldg - hematology contracts signed worth eur 4.65m ekf diagnostics holdings plc | ekf | 27.0 0 0.0% | mkt cap: 121.5m    rns number : 4937w ekf diagnostics holdings plc 26 august 2025     ekf diagnostics holdings plc ("ekf" or the "company")   hematology contracts signed worth eur 4.65m   ekf diagnostics holdings plc (aim: ekf), the aim-quoted global diagnostics business, announces that it has signed three new contracts in the key organic growth area of hematology point-of-care testing, worth approximately €4.65m (c. £4.03m), to be delivered over the next 12 to 24 months.   the contracts, for the supply of hemoglobin analysers and related consumables, have been secured by ekf's distribution partners in latin america and africa. one contract represents a return to significant sales in peru, following a sharp decline in local sales due to geo-political factors within the country. another contract marks ekf's first sales into uganda, as strong sales growth continues across africa.   the company successfully increased supply capacity going into h2 2025 to meet rising demand. with the order book already at record levels and now full for 2025, further investment will be deployed to grow hemoglobin consumable and analyser production capacity at the barleben site by 30% as part of the five-year strategic development plan for the business.   the additional contracts reinforce the board's confidence in delivering growth at the revenue and adjusted ebitda1 levels for fy 2025 in-line with market expectations2. the continued global expansion of ekf's hematology analyzer footprint also provides confidence in future growth as these continue to drive the pull through of consumables.   commenting, gavin jones, chief executive officer, said: "as part of our five-year strategic development plan to support accelerated organic growth, we identified that hemoglobin testing was the most significant growth opportunity within our poc portfolio. we're very pleased to see that allowing our dedicated poc sales team to focus on core growth products is bearing fruit, particularly in hemoglobin poc testing. as we win more and more new contracts and increase our global analyser footprint, we will see the benefits not just this year, but also in the years to come as consumable pull-through drives higher margin revenue growth."     1earnings before interest, tax, depreciation and amortisation, excluding exceptional items. ²management understands consensus revenue and adjusted ebitda forecasts for fy 2025 to be £53.6m and £12.4m respectively.   the person responsible for arranging the release of this announcement on behalf of the company is gavin jones, chief executive officer.   ekf diagnostics holdings plc www.ekfdiagnostics.com julian baines, executive chair  via walbrook pr gavin jones, chief executive officer   stephen young, chief financial officer   singer capital markets (nominated adviser & broker) tel: +44 (0)20 7496 3000 phil davies / oliver platts    walbrook pr limited tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com paul mcmanus / alice woodings  mob: +44 (0)7980 541 893 / +44 (0)7407 804 654       about ekf diagnostics holdings plc (www.ekfdiagnostics.com)   ekf is an aim-listed global diagnostics business focussed on:   ● point-of-care analysers in the key areas of hematology and diabetes  ● life sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.   ekf has headquarters in penarth (near cardiff) and operates five manufacturing sites across the us and germany, selling into over 120 countries world-wide.   this information is provided by rns, the news service of the london stock exchange. rns is approved by the financial conduct authority to act as a primary information provider in the united kingdom. terms and conditions relating to the use and distribution of this information may apply. for further information, please contact rns@lseg.com or visit www.rns.com.  rns may use your ip address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. for further information about how rns and the london stock exchange use the personal data you provide us, please see our privacy policy.   end   cntsewfieeisesa return to news summary

Label: Gestiegen